Nonhuman primate models in AIDS research

Current Opinion in HIV and AIDS

Volumn 8, Issue 4, 2013, Pages 255-261

  Evans, David T ^a   Silvestri, Guido ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

animal models; nonhuman primates; simian immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PREBIOTIC AGENT; PROBIOTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; RISK ASSESSMENT; SEXUAL TRANSMISSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; STEM CELL TRANSPLANTATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84880330645     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328361cee8     Document Type: Review

References (38)

1. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol 2012; 10:852-867.
2. Chahroudi A, Bosinger SE, Vanderford TH, et al. Natural SIV hosts: showing AIDS the door. Science 2012; 335:1188-1193.
3. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117-1134.
4. Stone M, Keele BF, Ma Z-M, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84:70837095.
5. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7557.
6. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathogens 2009; 5:e1000274.
7. Ma Z-M, Abel K, Rourke T, et al. A period of transient viremia and occult infection precedes persistent viremia and antiviral immune responses during multiple low-dose intravaginal simian immunodeficiency virus inoculations. J Virol 2004; 78:14048-14052.
8. McDermott AB, Mitchen J, Piaskowski S, et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 2004; 78:3140-3144.
9. Veazey RS, Shattock RJ, Klasse PJ, Moore JP. Animal models for microbicide studies. Curr HIV Res 2012; 10:79-87.
10. Paiardini M, Cervasi B, Reyes-Aviles E, et al. Low levels of SIV infection in sooty mangabey central-memory CD4\+ T-cells are associated with limited CCR5 expression. Nat Med 2011; 17:830-836.
11. Brenchley JM, Vinton C, Tabb B, et al. Differential infection patterns of CD4\+T cells and lymphoid tissue viral burden distinguish progressive and non-progressive lentiviral infections. Blood 2012; 120:4172-4181.
12. Okoye AA, Rohankhedkar M, Abana C, et al. Naive T cells are dispensable for memory CD4\+ T cell homeostasis in progressive simian immunodeficiency virus infection. J Exp Med 2012; 209:641-651.
13. Petrovas C, Yamamoto T, Gerner MY, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012; 122:3281-3294.
14. Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998-1008.
15. Zeng M, Paiardini M, Engram JC, et al. Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution. Blood 2012; 120:1856-1867.
16. Tabb B, Morcock DR, Trubey CM, et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 2013; 207:880-892.
17. Ortiz AM, Klatt NR, Li B, et al. Depletion of CD4 T cells abrogates postpeak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 2011; 121:4433-4445.
18. Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2012; 30:149-173.
19. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr 2011; 57:363-370.
20. Klatt NR, Canary LA, Sun X, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 2013. [Epub ahead of print]
21. Pandrea I, Cornell E, Wilson C, et al. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 2012; 120:1357-1366.
22. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
23. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.
24. Kearney M, Spindler J, Shao W, et al. Genetic diversity of simian immuno deficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol 2011; 85:1067-1076.
25. Shytaj IL, Norelli S, Chirullo B, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012; 8:e1002774.
26. Daniel MD, Kirchhoff F, Czajak SC, et al. Protective effects of a live-attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258:1938-1941.
27. Fukazawa Y, Park H, Cameron MJ, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012; 18:1673-1681.
28. Alpert MD, Harvey JD, Lauer WA, et al. ADCC develops over timeduring persis-tentinfection withlive-attenuatedSIV andisassociated withcompleteprotection against SIVmac251 challenge. PLoS Pathogens 2012; 8:e1002890.
29. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
30. Hessel AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-105.
31. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediate gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901-907.
32. Mudd PA, Watkins DI. Understanding animal models of elite control: windows on effective immune responses against immunodeficiency viruses. Curr Opin HIV AIDS 2011; 6:197-201.
33. Mudd PA, Martins MA, Ericsen AJ, et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012; 491:129-133.
34. Hansen SB, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-527.
35. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-94.
36. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
37. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
38. Apetrei C, Pandrea I, Mellors JW. Nonhuman primate models for HIV cure research. PLoS Pathog 2012; 8:e1002892.